CD BioGlyco has an advanced carbohydrate-based glycomedicine development platform and a range of analysis tools that will help customers study in vivo antitumor activity screening systematically. We have the confidence to be your essential research assistant in the field of glycobiology.
Cancer is a major public health burden in both developed and developing countries. Anticancer activity is the effect of natural and synthetic or biological and chemical agents to reverse, suppress or prevent carcinogenic progression. Therefore, it is important to review the different in vivo methods for estimating the anticancer properties of drugs.
Several in vivo methods have been developed to measure the efficiency of natural anticancer compounds and synthetic anticancer drugs. Usually, in vivo antitumor activity was studied on tumor-bearing mice. The activity was assessed by monitoring the mean survival time, tumor cell count, percentage increase in body weight, and effect on haematological parameters like red blood cell count, haemoglobin content, white blood cell count, and differential cell count.
Fig.1 The antitumor activity screening of chemical constituents. (Hou, et al., 2018)
CD BioGlyco offers assay services of the tumor growth inhibitory effect of glycomedicine on tumor-bearing nude mice. Our services include but are not limited to:
With a first-class experimental platform and professional research teams, CD BioGlyco provides customers with high-quality in vivo antitumor activity screening services according to their needs. If you are interested in our services, please contact us to obtain more information.
Reference: